
Willow Tree Research initiates coverage of Edgewise Therapeutics with a speculative buy rating and a $59 price target, suggesting about 40% upside from current levels. The key driver is the drug EDG-7500, which may offer improved tolerability without the need for routine safety echocardiograms, currently being tested in the STRATUS-HCM trial. The company is valued at around $4.6 billion with a strong cash position of approximately $1.74 billion, supporting operations into 2032. Risks include potential side effects like atrial fibrillation, competition, and manufacturing dependencies.
Edgewise Therapeutics shares are trading at USD 39.91 on Pluang, down 3.07% in the past day. The stock's market cap stands at $4.37 billion as of Nov 22, 2026 09:11 WIB.